Edinburgh dad's heartbreak as baby's everyday symptom leads to devastating diagnosis
An Edinburgh dad has opened up on his family's devastation after their son's first birthday party led to a rare diagnosis.
Marc Robson and his partner Melinda Garratt noticed their little boy Finley wasn't his usual self on the day of his party, and he started throwing up. Finley still wasn't feeling right the day after, so the family decided to call 111.
Melinda, 31, and Marc, 32, said they were advised to visit a pharmacist. They were told it may be due to Finley transitioning from formula to cow's milk, though this didn't help his condition.
READ MORE: Edinburgh police swoop on residential street as 'emergency incident' unfolds
READ MORE: Edinburgh dad's new career after going viral on Facebook 'by chance'
After several trips to A&E, Finley began vomiting blood. Finley was eventually rushed to Newcastle's Royal Victoria Infirmary, where doctors found a tumour on his brain.
Marc, who grew up in Edinburgh before starting a family in Newcastle, told Chronicle Live: "When we initially went to the RVI we thought it was going to be stomach issues, so hearing it was a tumour was very tough.
"The only way I can describe it is it was almost like I wasn't in my own body when I was hearing it. It was a strange feeling. Melinda was in tears."
Finley underwent an operation the following day which removed the majority of the tumour from his brain. Marc said: "They took him away from us at about 9.30am and we didn't see him again until 6.30pm. It was a very, very long day."
Sign up for Edinburgh Live newsletters for more headlines straight to your inbox
Approximately one week later the family received preliminary results which revealed the tumour could be one of four aggressive forms. And on Monday (June 23) the family received the heartbreaking news that Finley's tumour was the most aggressive of the four - an Atypical Teratoid Rhabdoid Tumor (ATRT) - an extremely rare form of brain cancer. Finley will now begin chemotherapy on Monday (June 30).
Marc said: "I'm not sure if it has even sunk in fully for us yet. We've had quite a few sleepless nights. It's so hard to explain what it's like hearing the news. It's almost as if you're watching someone else get that news.
"I think the next stage when he has the chemo is when it's going to hit the most. When we need to manage the treatment and his wellbeing even more than we already do.
"Contact with family and friends is going to be non-existent because of the side effects and his immune system going down. And when he loses his hair we've decided that we're going to shave it off to get it over and done with.
"The doctor recommended we do that too because we didn't realise but when babies go through this they can easily choke on their hair when they're sleeping. We'll shave it off when we feel that his scars have healed from his operation."
Finley will receive chemotherapy for the next five months before undergoing tests to see if it has been successful. Reflecting on how Finley has been coping with treatment, Marc said: "He doesn't talk other than he's recently started saying 'dada' so he can't really tell you what's wrong.
"But you can tell he's been in a lot of pain since the operation, which is normal. After his first operation he didn't really move much, he was sleeping a lot and couldn't lift his head up so we had to hold him.
Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages.
"He used to love rolling around but you could see that it was frustrating him when he was trying to move but he couldn't because he was in pain and he didn't quite understand why he was in pain."
The couple have set up a GoFundMe page to help ease the financial burden they have already encountered since Finley became unwell. Marc, who works as a business development manager for a company which provides maintenance for care homes, is currently receiving full pay.
However, he is unsure how much he will be able to work once Finley begins chemo. Melinda, who works for Lookers car sales company, is currently off work.
As well as helping to manage bills and any unexpected costs that arise as the couple navigate treatments and time away from work, the money raised will also help the couple with hospital parking fees and travel expenses. For more information and how to donate visit the GoFundMe page here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Parents face hurdles vaccinating children
Parents are being prevented from vaccinating their children because of obstacles such as difficulty booking appointments and a lack of reminders on what jabs are needed and when, a report suggests. Child health experts say "practical or logistical reasons" are discouraging families more often than fears over the vaccines. Vaccine uptake in the UK has fallen over the last decade, leading to outbreaks of measles and whooping cough. UK health officials say they are committed to working with the NHS to improve vaccine uptake among children. Since 2022, no childhood vaccine in the UK has met the World Health Organisation target of 95% of children vaccinated, which ensures protection of vulnerable people. As a result, measles and other preventable diseases have made a comeback. A commission of experts from the Royal College of Paediatrics and Child Health (RCPCH) spent a year looking at why. Dr Helen Stewart, officer for health improvement at RCPCH, said the steady decline in vaccination rates in a wealthy country like the UK was "extremely concerning". But she said vaccine hesitancy, when parents waver over getting their children vaccinated, "is only part of a very complex picture". "The reality is that there are many who simply need better support and easier access to appointments," Dr Stewart said. Although confidence in vaccines is still relatively high, the report found barriers to accessing jabs are why many families don't protect their children. Some of the most common barriers include: difficulties getting through to book appointments at GP surgeries difficulties getting time off work for appointments limited transport options or no parking at GP surgeries not seeing the same GP each time so lack of trust not being able to speak to a GP or nurse to ask about the vaccines lack of reminders for jabs being sent out from GP not enough clear information about what jabs their child needs and when "One of the findings of this new report is that parents have no easy way to check their child's vaccination status," says children's emergency medicine specialist, Dr Stewart. "When I ask if the child is up to date with their vaccinations, the most common response is 'I think so'." Poorer families, some ethnic minority groups and migrant communities are much less likely to be vaccinated, and these inequalities have become more obvious since the pandemic, the report says. It also notes an absence of health visitors often means parents have no one they feel comfortable discussing vaccines openly with. Rise of vaccine distrust - why more of us are questioning jabs The report recommends using NHS apps to improve the experience of booking jabs, investing and expanding vaccination services, and funding health visitors to deliver some of them. It also calls on the development of the 'digital red book' to be finalised so parents can keep track of their children's vaccinations. The NHS website lists the full schedule of vaccinations for children, from babies, up to the age of 15. Dr Julie Yates, deputy director for immunisation programmes at UK Health Security Agency, said plans were in place to improve childhood vaccine uptake by ensuring more flexible appointment booking systems, making vaccines more widely available across different locations, and making access easier in all communities. "Despite the challenges, it is also important to note that parents have high confidence in vaccinations with almost 90% agreeing vaccines are effective," Dr Yates said. Alison Morton, chief executive of the Institute for Health Visitors, said the report presented "a compelling case" to ensure babies and children are protected against serious diseases which can cause so much unnecessary harm. Helen Bedford, professor of children's health at University College London, said improvements needed investment in staff and infrastructure. "Our children have the right to be protected from preventable diseases which can cause illness, disability or even death," she said, adding that a fall in children getting their vaccines had resulted in the deaths of 11 young babies from whooping cough last year. Falling vaccinations among children isn't just an issue in the UK, in 2023 there were nearly 16 million children who had not had any vaccinations, most of them in south Asia and sub-Saharan Africa. Vaccination plea after measles cases rise in Scotland Millions of children at risk as vaccine uptake stalls Measles highest in 25 years in Europe, WHO says
Associated Press
4 hours ago
- Associated Press
Iksuda Therapeutics Receives FDA IND Clearance for IKS014
NEWCASTLE, England--(BUSINESS WIRE)--Jun 30, 2025-- Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IKS014, a human epidermal growth factor receptor 2 (HER2) ADC targeting patients with advanced HER2+ solid tumours, enabling the expansion of ongoing clinical trials. IKS014 is currently being investigated in an open-label phase 1 dose-escalation study ( ) designed to evaluate the safety and tolerability of increasing dose levels of IKS014 and establish a recommended phase 2 dose. Preliminary data from this study has demonstrated promising clinical activity across multiple tumour types, including breast, ovarian, gallbladder, and oesophageal cancers, and including patients who have relapsed after prior treatment with Enhertu. Gaining access to U.S. centres for the dose expansion stage of this phase 1 trial will enable efficient confirmation of the role of IKS014 in this important patient sub-set. Dr Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, said: 'The FDA clearance of our IND application for IKS014 represents a significant milestone in our mission to address the critical unmet needs of patients with HER2-positive cancers, particularly those who have exhausted current standard-of-care options. Early clinical data has been extremely encouraging, and we are excited to expand our program to reach more patients. 'The early efficacy signals that have been observed, particularly in patients that have relapsed after receiving prior treatments of Kadcyla and Enhertu, suggest IKS014 could potentially offer a new treatment option for patients who currently have limited alternatives. We look forward to working with our clinical partners to further evaluate the potential of IKS014.' The first stage of this phase 1 trial, to determine the recommended phase 2 dose for dose expansion, is nearing completion. The expansion phase will assess several patient cohorts including those with HER2-positive breast cancer who are refractory to or cannot tolerate Enhertu, patients with HER2-low breast cancer and patients with HER2-positive positive gastric cancer. The IND clearance will allow Iksuda to access patients across sites in the United States, alongside sites in Australia, New Zealand, and Singapore. The phase 1 trial is expected to complete in 2H 2026. About IKS014 IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index vs other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences ( ). About Iksuda Therapeutics: Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading antibody drug conjugates (ADCs) targeting difficult-to-treat haematological and solid tumours. Iksuda's pipeline of ADCs is centred on a portfolio of prodrug DNA and protein alkylating payloads in combination with stable conjugation chemistries including its proprietary PermaLink ® platform. The Company's design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer. View source version on CONTACT: For further information please contact: Iksuda Therapeutics Dave Simpson, Chief Executive Officer Tel: +44 (0) 191 6031680 [email protected] Consulting (Financial Media and IR) Simon Conway / Rob Winder / Amy Byrne Tel: +44 (0) 020 3727 1000 [email protected] KEYWORD: NORTH AMERICA UNITED STATES IRELAND UNITED KINGDOM EUROPE MASSACHUSETTS INDUSTRY KEYWORD: SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL ONCOLOGY HEALTH FDA CLINICAL TRIALS SOURCE: Iksuda Therapeutics Copyright Business Wire 2025. PUB: 06/30/2025 08:00 PM/DISC: 06/30/2025 08:00 PM
Yahoo
7 hours ago
- Yahoo
Lip-Filler Disaster Drives Millions to Watch on TikTok
In a spiraling series of TikTok videos posted over 72 hours, a U.K. woman documented her journey of getting her lip filler dissolved, except the procedure did anything but shrink the size of her lips. Instead, she essentially received the equivalent of a bee sting straight to the face. The saga, posted to the woman's account, @berthecn, enthralled social media onlookers, accumulating a whopping 14.7 million views. taken 4 antihistamines, hopefully goes down soon x The reaction was so alarming that the TikToker decided to call 111, the non-emergency phone number for the National Health Service (NHS) in the UK, who subsequently 'sent an ambulance out because it was deemed a potential allergic reaction.' In the Accident and Emergency department, she explained that she 'felt quite dizzy,' and 'almost fainted.' The ambulance ride made one thing clear: This wasn't just an unfortunate reaction—it was a real medical concern that required immediate attention. 'It's really scary,' the TikToker admitted in a clip, the reality of the situation hitting her. seeing as everyone has made me panic Once she arrived at the hospital, the woman was given IV steroids that helped reduce the swelling significantly after a few hours, but she also learned some shocking news. 'I found out that the solution used,' she explains, 'also has an enzyme that bees have in their sting. I've basically discovered that I may be allergic to a bee sting.' This enzyme, hyaluronidase, is used in filler dissolver to break down hyaluronic acid, according to a paper published in the Journal of Clinical and Aesthetic Dermatology on the safe use of hyaluronidase. (Hyaluronic acid is a substance that naturally occurs in the body and is often used in dermal fillers, as well as many skincare products, thanks to its moisture-retention and elasticity-boosting properties.) The authors say that 'wasp and bee stings contain more than one allergen, including hyaluronidase,' adding that cross-reactivity (when the immune system confuses one allergen for another similar one) can be a factor in these cases. Most people do not experience an anaphylactic reaction to fillers or filler desolvers, with the authors noting that the 'risk is extremely small and is lower than the quoted 0.1-percent incidence,' including delayed reactions and secondary exposure. The good news: Reactions like these, rare and frightening as they are, can usually be avoided. Patch tests are usually recommended when using a dermal filler dissolver that includes hyaluronidase in its formula, with a waiting period of 24 hours to catch delayed reactions. The bad news: Patch test guidelines aren't always followed as recommended. In this case, the woman said that her patch test was administered just a few minutes before her appointment. Despite this, the woman isn't eager to throw blame around for the incident. 'I don't want to fault this practitioner,' she said. 'She just made a mistake.' In an update posted to her account on June 30 (happily captioned with, 'I have my face back!), the woman shared the lessons she learned and insights she discovered about herself through the debacle. She tells her audience the swelling in her lips from the allergic reaction is 'almost fully dissolved.' I have my face back! Now, with her lips (almost) back to normal, she has realized she never needed filler to be happy in the first place, saying, 'I probably had complete body dysmorphia, because when I look at my lips now, I actually think they are beautiful.'
